CXCR4 and neuroendocrine carcinoma: Similarly, Weich et al. investigated 11 treatment-naïve patients with histologically proven neuroendocrine carcinomas (NEC), who underwent 18F-FDG and CXCR4-directed PET/CT for staging and therapy planning [47].